Promising clinical data from Kiadis Pharma’s lead product ATIR™ will be presented at the 51st American Society of Hematology’s (ASH) Annual Meeting

Biopharmaceutical company Kiadis Pharma announces the presentation of results obtained in two clinical trials with its lead product ATIR™. Dr. Denis Claude Roy will present data from a clinical study with ATIR™ in a mismatched stem cell transplantation setting. This study is performed in patients with no treatment options left and having no matched donor available for a standard transplantation procedure. Dr. Stephan Mielke will present clinical data with ATIR™ in a matched stem cell transplantation setting. Both presentations will take place at the 51st ASH Annual Meeting to be held on December 5 - 8, 2009 at the Ernest N. Morial Convention Center in New Orleans, USA.
 
Presentation of the sponsor initiated clinical phase I/II study on mismatched transplantations by Dr. Denis-Claude Roy

Abstract: Haploidentical Stem Cell Transplantation: High Doses of Alloreactive-T Cell Depleted Donor Lymphocytes Administered Post-Transplant Decrease Infections and Improve Survival without Causing Severe Gvhd

Session Name: Clinical Care - Acute and Chronic GVHD, Infectious Complications and Immune Reconstitution of Transplantation: Immunology of Acute and Chronic Graft-versus-Host Disease
Session date: Monday, December 7, 2009
Session time: 2:45 PM - 4:15 PM
Presentation time Dr. Roy: 3:00 PM
Location: Ernest N. Morial Convention Center, 243-245

Presentation of the physician initiated NIH clinical phase II study of Kiadis Pharma’s product ATIR™ by Dr. Stephan Mielke*

Abstract: Allografts Selectively Photodepleted of GvHD Causing T Cells and Followed by Low-Level Immunosuppression: A Novel Method to Improve Disease Control After HLA-Matched Sibling Transplantations

Session Name: Clinical Care - Acute and Chronic GVHD, Infectious Complications and Immune Reconstitution of Transplantation: Immunology of Acute and Chronic Graft-versus-Host Disease
Session date: Monday, December 7, 2009
Session time: 2:45 PM - 4:15 PM
Presentation time Dr. Mielke: 3:45 PM
Location: Ernest N. Morial Convention Center, 243-245

About ATIR™
ATIR™, a donor lymphocyte preparation depleted of alloreactive T-cells, is under development to reduce transplant related mortality (TRM) following an allogeneic hematopoietic stem cell transplantation (HSCT). ATIR™ is designed to provide early immune reconstitution to fight infections and remaining tumor cells while preventing acute severe (Grade III/IV) GvHD and therefore significantly improves the outcome of the transplant procedure. Moreover, it enables the use of a mismatched, related (haplo-identical) donor, thereby providing virtually everyone with an immediately available donor and treatment.

About Kiadis Pharma
Kiadis Pharma is an oncology focused biopharmaceutical development company with cell based products in clinical development. The company develops products that offer novel treatment options for terminally ill cancer patients and address significant unmet medical needs. The key focus indication for Kiadis Pharma is limitations and complications of bone marrow transplantation procedures. Kiadis Pharma is located in Amsterdam, The Netherlands. For more information about Kiadis Pharma, please visit www.kiadis.com.

* Dr. Stephan Mielke is currently working at the Julius-Maximilians University of Würzburg, Germany.

For more information please contact:
Kiadis Pharma B.V.
Eefje Simpelaar
Director Communications
Email: e.simpelaar@kiadis.com
Tel: +31 20 3140250
Mob: +31 6 10829344